Key Takeaways TMDX reported Q4 EPS of 57 cents, up 200% year over year, beating estimates by 39%.TransMedics posted 32% revenue growth in Q4, driven by the Organ Care System and logistics expansion.TMDX sees 2026 revenues of $727M-$757M, implying 20-25% growth over 2025 levels.TransMedics Group (TMDX) delivered earnings per share (EPS) of 57 cents in the fourth quarter of 2025, excluding a one-time benefit related to deferred tax assets, which surged 200% year over year. The figure surpassed the Zacks Conse ...

Industry Overview - Genomics is the comprehensive study of genomes, which has intensified interest among pharmaceutical and biotechnology companies for deeper insights into disease biology and effective therapeutic strategies [1] - The global genomics market was valued at $34.23 billion in 2025 and is projected to grow from $38.24 billion in 2026 to $99.26 billion by 2034, reflecting a compound annual growth rate (CAGR) of 12.66% [8] - The global synthetic biology market was valued at $18.94 billion in 2025 and is expected to reach $69.18 billion by 2033, with a CAGR of 17.7% from 2026 to 2033 [8] Genomic Research and Applications - Insights from genomic research are increasingly used to evaluate patient responses to specific drugs, driving the development of targeted treatments and advancing personalized medicine [3] - The emergence of genome-editing technologies, particularly CRISPR/Cas9 systems, is enabling precise modifications to DNA, offering potential cures for diseases caused by genetic mutations [7] Key Companies - Illumina (ILMN) is a prominent player in genomic sequencing, recognized for its leadership in sequencing and array-based technologies [5] - Pacific Biosciences of California (PACB) focuses on advanced sequencing solutions and has seen its shares rise by 9.1% in the past year, currently holding a Zacks Rank 1 (Strong Buy) [10][12] - Caribou Biosciences (CRBU) is a clinical-stage CRISPR genome-editing biopharmaceutical company, with shares surging 34.4% in the past year and a Zacks Rank 2 (Buy) [12][14] - Sana Biotechnology (SANA) is developing cell engineering platforms for diseases like type 1 diabetes and has seen its shares increase by 37.5% over the past year, also holding a Zacks Rank 2 [15][17]

MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference on Monday, March 2, 2026, at 2:30 PM ET in Boston, MA. A live webcast of the event can be accessed at the company’s investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the ...

Core Insights - Cathie Wood's ARK Invest is shifting its investment focus towards early-stage biotechnology companies while reducing exposure to consumer technology, diagnostics, and space technology sectors [1][2] Group 1: Biotechnology Investments - ARK Invest has significantly increased its holdings in gene editing and genomics, particularly buying over 195,000 shares of Beam Therapeutics (BEAM.US), with a market value of approximately $5.4 billion [1] - The firm also acquired about 236,000 shares of Intellia Therapeutics (NTLA.US), which utilizes CRISPR technology for gene repair, aligning with its strategic focus [2] - Additional investments include over 423,000 shares of Pacific Biosciences of California (PACB.US) and 101,000 shares of Twist Bioscience (TWST.US), emphasizing a commitment to genomic discoveries and precision medical tools [2] Group 2: Adjustments in Holdings - ARK is systematically adjusting its portfolio in the medical and technology sectors, reducing its stake in Ionis Pharmaceuticals (IONS.US) by 26,645 shares and scaling back on Natera (NTRA.US) and Guardant Health (GH.US) [3] - The flagship ARK Innovation ETF has executed structural adjustments, selling over 72,000 shares of Roku (ROKU.US) and more than 29,000 shares of Shopify (SHOP.US) [4] - Despite selling over 633,000 shares of Tesla (TSLA.US), it remains the largest holding in ARK's portfolio, which has outperformed major U.S. benchmark indices [4]

Core Viewpoint - The current rotation within ARK Invest indicates a strong belief that 2026 will be a pivotal year for the genomic revolution [1] Group 1: Investment Strategy - ARK Invest is significantly reducing its holdings in legacy winners like Tesla and Rocket Lab to invest millions in gene-editing companies [2] - The firm is focusing on acquiring shares of CRISPR Therapeutics, Intellia Therapeutics, Beam Therapeutics, and Pacific Biosciences as 2025 ends [3] Group 2: Thematic Focus - Cathie Wood's investment thesis combines artificial intelligence with programmable biology, emphasizing AI's transformative potential in healthcare [4] - The multiomics flywheel framework suggests that AI enhances all aspects of multiomics, from biological data generation to disease diagnosis and drug development [4] Group 3: Technological Advancements - Improved algorithms are making gene sequencing faster, while cheaper sequencing provides more data for AI learning, leading to breakthroughs in gene editing and new treatment possibilities [5] Group 4: Holdings Overview - By late December 2025, ARK increased its stake in CRISPR Therapeutics to over 5% of the ARKK Innovation Fund, with Beam Therapeutics at 3.41%, Twist at 2%, and Intellia at 1.14% [6] - ARK also manages the Ark Genomic Revolution Fund, which invests in companies across healthcare and information technology relevant to the genomics theme [6]

Tesla Trade - Ark Invest sold 60,715 shares of Tesla across multiple ETFs, with a total transaction value of approximately $29.7 million, as the stock closed at $488.73 [2] - Concerns regarding Tesla's financial prospects were raised by Gerber Kawasaki, particularly about achieving GAAP profitability, although the company's market share in the EV sector remains strong [3] Palantir Trade - Ark Invest reduced its position in Palantir by selling 47,309 shares, valued at approximately $9.2 million, with the stock closing at $193.98 [4] - BofA Securities expressed optimism about Palantir's growth, citing strong momentum in its U.S. commercial business and a recent two-year $448 million government order [5] Shopify Trade - Ark Invest sold 33,164 shares of Shopify, valued at approximately $5.6 million, with a closing price of $169.67 [6] - Shopify's recent Winter 2026 Edition showcased expanded capabilities in AI and merchant tools, reinforcing confidence in its long-term growth according to JPMorgan [7] WeRide Trade - Ark Invest purchased 520,697 shares of WeRide, valued at approximately $4.7 million, with the stock closing at $8.97 [8] - WeRide launched public Robotaxi rides in Dubai, marking progress towards a fully driverless rollout planned for early 2026 [9] Other Key Trades - Ark Invest acquired 78,793 shares of CRISPR Therapeutics across ARKG and ARKK [10] - Intellia Therapeutics saw an acquisition of 187,880 shares via ARKG and ARKK, while Rocket Lab sold 232,425 shares through ARKQ and ARKX [12]

Group 1 - U.S. stock futures are higher, with Nasdaq futures gaining approximately 100 points [1] - Novo Nordisk A/S shares fell 9.3% to $43.22 in pre-market trading after Phase 3 trial data showed GLP-1 drugs did not significantly reduce Alzheimer's disease progression [1] Group 2 - Geospace Technologies Corp shares tumbled 13.7% to $11.05 in pre-market trading after a 26% decline on Friday [3] - Inventiva ADR shares declined 6.1% to $4.04 in pre-market trading, reporting its cash position and revenues for the first nine months of 2025 [3] - Datavault AI Inc shares fell 5.8% to $2.40 in pre-market trading after a 46% gain on Friday [3] - Waldencast PLC shares declined 5.5% to $2.91 in pre-market trading following the release of second-quarter operating results and a third-quarter trading update [3] - Pacific Biosciences of California Inc shares decreased 4.1% to $2.13 in pre-market trading after an 18% gain on Friday [3] - American Axle & Manufacturing Holdings Inc shares fell 3.7% to $6.00 in pre-market trading after a 7% gain on Friday [3] - Hafnia Ltd shares declined 3.4% to $6.20 in pre-market trading [3] - Getty Images Holdings Inc shares fell 3.3% to $1.46 in pre-market trading after a 7% gain on Friday [3]

Group 1 - U.S. stock futures are higher, with Nasdaq futures gaining approximately 100 points [1] - Novo Nordisk A/S shares fell 9.3% to $43.22 in pre-market trading after Phase 3 trial data showed GLP-1 drugs did not significantly reduce Alzheimer's disease progression [1] Group 2 - Geospace Technologies Corp shares tumbled 13.7% to $11.05 in pre-market trading after a 26% decline on Friday [3] - Inventiva ADR declined 6.1% to $4.04 in pre-market trading, reporting its cash position and revenues for the first nine months of 2025 [3] - Datavault AI Inc fell 5.8% to $2.40 in pre-market trading after a gain of over 46% on Friday [3] - Waldencast PLC declined 5.5% to $2.91 in pre-market trading following its second-quarter operating results and third-quarter trading update [3] - Pacific Biosciences of California Inc declined 4.1% to $2.13 in pre-market trading after an 18% gain on Friday [3] - American Axle & Manufacturing Holdings Inc fell 3.7% to $6.00 in pre-market trading after a 7% gain on Friday [3] - Hafnia Ltd declined 3.4% to $6.20 in pre-market trading [3] - Getty Images Holdings Inc fell 3.3% to $1.46 in pre-market trading after a 7% gain on Friday [3]

Industry Overview - Genomics is a comprehensive study of genomes, focusing on the complete set of DNA in an organism, and is gaining interest from pharmaceutical and biotechnology companies due to recent breakthroughs [1] - The distinction between genetics and genomics is important; genetics focuses on individual genes, while genomics aims to characterize all genes and their interactions within a living system [2] - Insights from genomics are increasingly used to develop targeted treatments and advance personalized medicine, addressing the rising demand for innovative medical therapies [3] Technological Advancements - The field of genomics has led to the emergence of synthetic biology, which applies engineering principles to biology for applications such as drug discovery and gene editing [4] - Significant progress in genomics has been driven by reductions in the cost, time, and effort required for genome sequencing, with Illumina being a major player in this space [5] - Genome-editing technologies, particularly CRISPR/Cas9, are being explored by companies like CRISPR Therapeutics AG and Intellia Therapeutics to treat diseases caused by genetic mutations [7] Market Projections - The genomics market is projected to reach $80.17 billion by 2032, while the synthetic biology market was valued at $16.2 billion in 2024 and is expected to grow at a CAGR of 17.30% from 2025 to 2030 [8] Investment Opportunities - Companies such as Editas Medicine, Sana Biotechnology, and Pacific Biosciences of California are highlighted as potential investment opportunities in the genomics and synthetic biology sectors [9] - Editas Medicine is developing EDIT-401, a gene editing therapy aimed at reducing LDL-cholesterol, showing over 90% reduction in preclinical tests [10][11] - Sana Biotechnology is focusing on cell engineering platforms for diseases like type 1 diabetes and B-cell cancers, with plans for IND applications in 2026 and 2027 [15][16][17] - Pacific Biosciences of California specializes in advanced sequencing solutions, with a focus on HiFi long-read sequencing technology, and has seen a 53.9% increase in shares over the past six months [18][19]

Core Insights - U.S. stocks experienced an upward trend, with the Nasdaq Composite increasing by approximately 1% on Friday [1] - Cloudflare, Inc. reported better-than-expected third-quarter financial results, leading to a significant rise in its stock price [1][2] Company Performance - Cloudflare's quarterly earnings were 27 cents per share, surpassing the Street estimate of 23 cents [2] - The company's quarterly revenue reached $562.02 million, exceeding the analyst estimate of $544.82 million [2] - Following the earnings report, Cloudflare shares surged by 12.6% to $250.73 [2] Other Notable Stock Movements - AMTD Digital Inc. saw a remarkable 157% increase in its stock price to $4.34 after reporting a 1,085.9% year-over-year revenue increase to $73.2 million for the six months ending April 30 [4] - LexinFintech Holdings Ltd. gained 26% to $4.85, while Brighthouse Financial, Inc. rose 25.4% to $57.28 [4] - Illumina, Inc. surged 21% to $119.88 after reporting third-quarter results above estimates and raising its full-year guidance [4] - Reddit, Inc. shares increased by 17.8% to $229.10 after reporting better-than-expected third-quarter results and issuing optimistic fourth-quarter sales guidance [4] - Amazon.com, Inc. rose 11% to $247.26 following positive quarterly results [4]